
    
      SAR302503 (TG101348) is a potent small molecule inhibitor of Janus kinase 2 (JAK2). This is
      an extension study for a first-in-man, dose escalation study (MF-TG101348-001). The safety,
      tolerability and clinical activity of SAR302503 (TG101348) in subjects with myelofibrosis
      will be evaluated.
    
  